Background: The germinal center (GC) resident T follicular helper cells (Tfh) represent a significant fraction of total pool of HIV/SIV infected cells during chronic infection and HAART. The GC are generally thought to exclude CD8 T cells and antiviral CD8 T cells with potential to migrate to GC (follicular CD8) may enhance HIV/SIV control and reduce viral reservoirs. Here we studied the follicular CD8 in a cohort of DNA/MVA vaccinated rhesus macaques (RM) that controlled or did not control a pathogenic SIV infection. Methods: RM were vaccinated with a DNA/MVA SIV vaccine and challenged intrarectally with SIVmac251. Animals with viral load below 1,000 copies at set point were defined as controllers. All controller RM (n = 19) were vaccinated and noncontroller RM (n = 18) consisted of both vaccinated and unvaccinated.
Results: Post challenge, we observed an aberrant enrichment of SIV + PD-1 hi CD4 T cells in the LN and rectum of non-controllers but not controllers. The enhanced viral control was associated with higher frequency of Gag CM9 Tet + CD8 T cells in the LN of controller RM compared to non-controller RM. This was not evident in blood. Interestingly, a significant fraction of anti-viral CD8 T cells in the controller RM co-expressed CXCR5 (required for homing to B cell follicles/GC). The frequency of Tet + CXCR5 + granzyme B + cells was also higher in the LN of controller RM and higher frequencies correlated with lower Tfh and enhanced viral control. Immunofluorescence staining revealed co-localization of CD8 T cells with PD-1 bright cells in IgD-GC, a phenomena not observed in the non-controller RM. Impressively, the CXCR5 + CD8 T cells from the controller RM restricted the anti-CD3 driven expansion of CM9 peptide pulsed Tfh cells in vitro suggesting their killing potential. Conclusions: Our results reveal a novel subset of anti-viral CD8 T cells that may contribute to enhanced control of pathogenic SIV infection by infiltrating to GC of lymphoid sites and limiting SIV replication in Tfh in a vaccine setting. Background: A top-down strategy was used to search for beneficial viral targets in large human immunogenicity data and to identify potential decoy targets that should be avoided in future vaccine designs. Methods: Through the identification of beneficial T cell responses in more than 1000 individuals, the HIVACAT T-cell immunogen (HTI) was designed to contain 16 HIV-1 protein segments of 10-70 amino acids in length, covering > 50 optimal defined CD4 + and CD8 + T-cell epitopes with > 40 different HLA restrictions, without overrepresentation of B27/B57/B58 restricted epitopes. Heterologous prime-boost regimens combining DNA (D) and MVA (M) expressing HTI were assessed in C57BL/6 mice and four Indian rhesus macaques. Cellular responses were characterized using IFN-c ELISPOT and intracellular cytokine assays. Results: In C57BL/6 mice, DNA.HTI induced broad CD4
+ and CD8 + T-cell responses to all segments within Gag, Pol, Vif and Nef. These responses were strongly increased by using heterologous regimens consisting of 3x DNA.HTI prime followed by MVA.HTI boost compared to 3 or 4x DNA.HTI only (median magnitude DDDM of 3,051 vs 1,401 and 1,353 SFC/10 6 splenocytes in DDD and DDDD groups respectively, p = 0.0087). In rhesus macaques, DDD (administered IM in combination with macaque IL-12 DNA as molecular adjuvant using in vivo electroporation) induced 0.4-1.5 % of specific T cells that persisted over a period of 4.5 months. MVA.HTI boosted the responses by 3-to 20-fold, reaching 0. 
